Publications
Detailed Information
A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lim, Sun Min | - |
dc.contributor.author | Cho, Byoung Chul | - |
dc.contributor.author | Kim, Sang-We | - |
dc.contributor.author | Kang, Seok Yun | - |
dc.contributor.author | Heo, Dae Seog | - |
dc.contributor.author | Kim, Heung Tae | - |
dc.contributor.author | Lee, Dae Ho | - |
dc.contributor.author | Kim, Dong-Wan | - |
dc.contributor.author | Jung, Minkyu | - |
dc.contributor.author | Choi, Jin-Hyuk | - |
dc.contributor.author | Shim, Hyo Sup | - |
dc.contributor.author | Choi, Jong Rak | - |
dc.contributor.author | Kim, Joo-Hang | - |
dc.date.accessioned | 2020-04-27T11:17:15Z | - |
dc.date.available | 2020-04-27T11:17:15Z | - |
dc.date.created | 2018-08-22 | - |
dc.date.issued | 2016-03 | - |
dc.identifier.citation | Lung Cancer, Vol.93, pp.1-8 | - |
dc.identifier.issn | 0169-5002 | - |
dc.identifier.other | 45472 | - |
dc.identifier.uri | https://hdl.handle.net/10371/165334 | - |
dc.description.abstract | Objectives: Sorafenib and erlotinib are potent, orally administered receptor tyrosine kinase inhibitors with antiproliferative and antiangiogenic activities. Given their synergistic activity in combination, we conducted a phase II study to determine the clinical activity of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (NSCLC). Materials and methods: Patients with advanced NSCLC who have received one or two prior chemotherapy regimens for metastatic disease, ECOG 0-2, and adequate organ function were eligible. Patients received 400 mg twice daily sorafenib and 150 mg daily erlotinib in 28-day cycles. Epidermal growth factor receptor mutation and its downstream pathways were analyzed from available tumor samples. Changes in plasma cytokine and angiogenic factors were correlated with clinical outcomes. Results: A total of 46 patients were enrolled. Twenty patients (43%) were never smokers and 35 patients (75%) had adenocarcinoma histology. The overall response rate was 30.4%. Response to sorafenib/erlotinib was observed more commonly in patients with EGFR mutation than in those with EGFR wild type (WT) or EGFR unknown tumors (62.5% vs. 6.7% vs. 34.8%; P = 0.013). Likewise, DCR was higher among patients with EGFR mutation than in those with EGFR WT or EGFR unknown tumors (87.5% vs. 46.7% vs. 60.9%; P = 0.161). The most frequent adverse events (AEs) of all grades were hand-foot skin reaction (67.4%) followed by acneiform rash (58.7%). Conclusion: Sorafenib combined with erlotinib is well-tolerated with manageable toxicity and appears to be effective against advanced NSCLC with one or two prior line of systemic treatment (NCT00801385). (C) 2015 Elsevier Ireland Ltd. All rights reserved. | - |
dc.language | 영어 | - |
dc.publisher | Elsevier BV | - |
dc.title | A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806) | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 김동완 | - |
dc.contributor.AlternativeAuthor | 허대석 | - |
dc.identifier.doi | 10.1016/j.lungcan.2015.12.005 | - |
dc.citation.journaltitle | Lung Cancer | - |
dc.identifier.wosid | 000371838700001 | - |
dc.identifier.scopusid | 2-s2.0-84959375751 | - |
dc.citation.endpage | 8 | - |
dc.citation.startpage | 1 | - |
dc.citation.volume | 93 | - |
dc.identifier.sci | 000371838700001 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Heo, Dae Seog | - |
dc.contributor.affiliatedAuthor | Kim, Dong-Wan | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | GROWTH-FACTOR RECEPTOR | - |
dc.subject.keywordPlus | TUMOR ANGIOGENESIS | - |
dc.subject.keywordPlus | ANTITUMOR-ACTIVITY | - |
dc.subject.keywordPlus | PLUS ERLOTINIB | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | BEVACIZUMAB | - |
dc.subject.keywordPlus | EGFR | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | INHIBITOR | - |
dc.subject.keywordAuthor | Non-small-cell lung cancer | - |
dc.subject.keywordAuthor | Sorafenib | - |
dc.subject.keywordAuthor | Erlotinib | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.